Accession | SAMC1676189 |
---|---|
Accession in Other Database | GSA-Human: HRS285456 |
Sample name | Sample3 |
Title | Panel sequencing of P001_3 |
Sample type | Human sample |
Organism | Homo sapiens |
Description | Targeted sequencing of tumor samples of P001_3 |
Attributes | *This sample record contains additional controlled-access information that is avaiable from GSA-Human by requesting study HRA001346 in the GSA-Human system. |
Release date | 2021-09-23 |
BioProject Accession | PRJCA005206 |
Submitter | xian zhang (guowei@cicams.ac.cn) |
Organization | Geneseeq Technology Inc. |
Submission date | 2023-06-18 |
Resource name | Description |
---|---|
GSA-Human (1) | - |
HRA001346 (Controlled Access) | Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluated the clinical utility of circulating tumor DNA (ctDNA) for dynamic recurrence risk and adjuvant chemotherapy (ACT) benefit prediction in resected non-small cell lung cancer (NSCLC). |